Sunshine Biopharma announced that its wholly owned Canadian subsidiary, Nora Pharma Inc., has launched two new generic prescription drugs. The first product is Varenicline, a generic version of Champix. Varenicline is used as a smoking cessation product and is available in formats of 0.5 mg and 1 mg tablets, as well as a starter kit. The second is Betahistine, a generic version of Serc, to treat patients with vertigo. Betahistine is available in formats of 8 mg, 16 mg and 24 mg scored tablets. “Propelled by Sunshine Biopharma’s strategic support, Nora Pharma plans to continue its rapid top-line and bottom-line growth,” said Malek Chamoun, president of Nora Pharma.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SBFM:
- Sunshine Biopharma’s Nora Pharma launches two generic prescription drugs
- Sunshine Biopharma announces publication of coronavirus research results
- Sunshine Biopharma launches nine generic prescription drugs in 2024
- Sunshine Biopharma’s Revenues and Profits Surge
- AMD to acquire ZY Systems, Estee Lauder reports Q4 beat: Morning Buzz